Tony Hagen | Authors

November 12, 2019

Testing for driver mutations is essential before initiating therapy in patients with non–small cell lung cancer, because there is a risk that the type of upfront treatment chosen could add to the toxicity of, and spur resistance to, targeted therapy options, Suresh S. Ramalingam, MD, said at the 14th Annual New York Lung Cancers Symposium.

November 10, 2019

Noeadjuvant therapy for lung cancer provides significant benefits compared with adjuvant therapy, according to Jamie E. Chaft, MD. In a presentation at the 14th Annual New York Lung Cancers Symposium, Chaft explained why neoadjuvant therapy is beneficial even though adjuvant therapy is still the standard of care at a number of cancer centers.

June 04, 2019

Announced at the 2019 ASCO Annual Meeting, the FDA is rolling out a pilot program that will provide more information and assistance for acquiring expanded access (EA) to investigational therapies for both oncologists and patients. The program is being called Project Facilitate.

June 02, 2019

Details on a prototype system were released during the 2019 ASCO Annual Meeting by a consortium of cancer care institutions that was designed to use electronic health record systems to provide real-world patient data that could guide research and improve cancer treatment.

March 08, 2019

Although prognostic indices for mantle cell lymphoma can be useful in the classification of patients, it does little in guiding treatment decisions. Instead of relying on these indices, Simon Rule, MD, advocates for a watch-and-wait approach to managing certain patients with mantle cell lymphoma.

March 04, 2019

Jacqueline C. Barrientos, MD, MS, discusses emerging agents and combinations in CLL based on recent trial data.